“VIS-101 was purpose-designed with durability in mind.” Cadmus Rich, MD, MBA, chief medical officer, Visara
Visara Doses First Patient in Phase 2b Trial Pitting Bispecific VIS-101 Against Aflibercept in Wet AMD
Key Takeaways
- ASCEND randomizes ~244 treatment-naïve wet AMD patients to VIS-101 6 mg, VIS-101 9 mg, or aflibercept 2 mg q8w, using quadruple masking and head-to-head active control.
- Uniform retreatment criteria across arms through Month 9 follow three monthly loading injections, enabling comparative assessment of durability with intervals extending up to seven months post-loading.
Visara has dosed the first patient in ASCEND, a roughly 244-patient, head-to-head phase 2b trial comparing two doses of its tetravalent VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in treatment-naïve wet AMD. The study will test dosing intervals of up to seven months and select the dose for a global phase 3 program planned as early as 2027.
Visara, a majority-owned ophthalmology subsidiary of NovaBridge Biosciences, announced on November 18, 2026, that the first patient has been dosed in ASCEND, a phase 2b trial of VIS-101 in wet age-related macular degeneration (AMD).¹ VIS-101 is a tetravalent, bispecific inhibitor of vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (ANG-2) designed for efficacy and durability.¹
ASCEND is a randomized, quadruple-masked, active-controlled, head-to-head study enrolling about 244 treatment-naïve patients with wet AMD.¹ The goal, according to Jeffrey Nau, PhD, MMS, president and chief executive officer of Visara, is to “maintain strong disease control while enabling patients to go substantially longer between injections.”¹
How is the ASCEND trial designed?
Patients are randomized to VIS-101 6 mg, VIS-101 9 mg, or aflibercept 2 mg, the standard-of-care comparator dosed every 8 weeks.¹ All patients receive three monthly loading doses, followed by retreatment based on protocol criteria that are the same across groups through Month 9.¹ The study evaluates treatment intervals of up to seven months after loading.¹
The trial is designed to determine the dose or doses for phase 3 and to establish initial durability.¹ ASCEND is being conducted in China in partnership with Everest Medicines.¹ Visara holds global rights to VIS-101 outside Greater China and certain Asian territories.²
What did earlier data show?
In a randomized, dose-ranging phase 2a study in China, 38 patients with wet AMD received VIS-101 6 mg (n = 25) or 3 mg (n = 13).² VIS-101 produced mean best-corrected visual acuity improvements of more than 10 Early Treatment Diabetic Retinopathy Study letters, and the company described the responses as rapid and durable with a favorable safety profile.² About 50% of patients in the 6 mg treatment-naïve cohort remained retreatment-free six months after the last loading dose.¹
“VIS-101 was purpose-designed with durability in mind,” said Cadmus Rich, MD, MBA, chief medical officer of Visara.¹ Visara says the bispecific, tetravalent format provides more binding sites and increased affinity and avidity for VEGF-A and ANG-2.¹
Why target both VEGF-A and ANG-2?
ANG-2 is upregulated in the retina and vitreous in neovascular AMD, where it destabilizes blood vessels and sensitizes them to VEGF-A.³ Roche’s faricimab (Vabysmo), a bispecific antibody against both targets, validated the approach in the phase 3 TENAYA and LUCERNE trials, in which faricimab dosed up to every 16 weeks was noninferior to aflibercept every 8 weeks for visual acuity across 1,329 patients.³ Nearly half of faricimab-treated patients were on 16-week dosing at Week 48, and rates of ocular adverse events were comparable between the two arms.³
Developers are now working to push intervals further. BioPharm International® recently reported on
Multispecific design is central to that push. In a BioPharm International
What happens next?
VIS-101 has completed initial safety and dose-escalation studies in the United States and China, and it is also in development for diabetic macular edema and retinal vein occlusion.¹ Visara plans to start a global phase 3 program as early as 2027.¹ The company has not disclosed when ASCEND results are expected.
References
Visara announces first patient dosed in ASCEND phase 2b trial of VIS-101 in wet AMD . News release. NovaBridge Biosciences; November 18, 2026. Accessed November 18, 2026.NovaBridge and Visara announce positive results from VIS-101 phase 2a wet AMD study . News release. NovaBridge Biosciences; March 9, 2026. Accessed November 18, 2026.- Heier JS, Khanani AM, Quezada Ruiz C, et al.
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials . Lancet. 2022;399(10326):729-740. doi:10.1016/S0140-6736(22)00010-1
Related to this article









